Yazarlar : Czuczman MS, Fayad L, Delwail V, et al

Yayın : Blood

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22389254

Konu : Lenfoma

Literatür İçeriği :  

Abstract

New treatments are required for rituximab-refractory follicular lymphoma (FL). Patients with rituximab-refractory FL received 8 weekly infusions of ofatumumab (CD20 monoclonal antibody; dose 1, 300 mg; doses 2-8, 500 or 1000 mg; N=116). Median age was 61 years, 47% had high-risk FLIPI scores, 65% were chemotherapy-refractory, and median number of prior therapies was 4. Overall response rate (ORR) was 13% and 10% for the 500-mg and 1000-mg arms, respectively. Among 27 patients refractory to rituximab monotherapy, ORR was 22%. Median progression-free survival (mPFS) was 5.8 months. Forty-six percent of patients demonstrated tumor reduction 3 months after therapy initiation; mPFS for these patients was 9.1 months. Most common adverse events included infections, rash, urticaria, fatigue, and pruritus. Three patients experienced grade 3 infusion-related reactions; none were considered serious events. Grade 3-4 neutropenia, leukopenia, anemia, and thrombocytopenia occurred in a subset of patients. Ofatumumab was well-tolerated and modestly active in this heavily pretreated, rituximab-refractory population and is being studied in less refractory FL and in combination with other agents in various B-cell neoplasms. This study was registered at www.clinicaltrials.gov as NCT00394836

Literatür Arşivi